Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
SCORES
3 other identifiers
interventional
54
1 country
1
Brief Summary
This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 28, 2021
CompletedFirst Submitted
Initial submission to the registry
November 11, 2021
CompletedFirst Posted
Study publicly available on registry
November 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
November 24, 2025
November 1, 2025
4.6 years
November 11, 2021
November 19, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Processing Speed domain score from the MATRICS Consensus Cognitive Battery (MCCB)
Change in processing speed domain score and individual measures within the domain.
Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)
Secondary Outcomes (2)
Global Functioning: Social (GF:Social) scale (Phase 2/R33 only)
Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)
SIPS/SOPS: Positive Symptoms (Phase 2/R33 only)
Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)
Study Arms (2)
Speeded Cognitive Training
EXPERIMENTALParticipants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of speeded cognitive training tasks on cognition and social function.
Non-Speeded Cognitive Training
ACTIVE COMPARATORParticipants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of non-speeded cognitive training tasks on cognition and social function.
Interventions
This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention. In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB. The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention.
Eligibility Criteria
You may qualify if:
- Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis Risk Syndromes, defined by the presence of at least one attenuated positive symptom at a moderate to severe level
- A score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB).
You may not qualify if:
- Any DSM 5 Schizophrenia-Spectrum diagnosis
- Non-English speaking
- Past or current history of a clinically significant central nervous system disorder (e.g., seizure disorder)
- Estimated IQ\<70
- Significant head injury
- Significant substance abuse
- Significant visual or auditory impairment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Northwell Healthlead
- National Institute of Mental Health (NIMH)collaborator
Study Sites (1)
Northwell Health- The Zucker Hillside Hospital
Glen Oaks, New York, 11042, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ricardo E Carrion, Ph.D.
Northwell Health
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 11, 2021
First Posted
November 23, 2021
Study Start
October 28, 2021
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
May 31, 2026
Last Updated
November 24, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- We plan to make all data collected available as a national resource to the broader scientific community for investigators wishing to pursue their own analyses. Consistent with the NIH policy regarding data sharing, we will share data no later than following acceptance for publication of the main findings from the final dataset, which is expected to occur at the end of year 5. We request that we maintain exclusive access to these data until the end of year 5 to ensure an adequate amount of time for the PIs to conduct analyses and prepare manuscripts for publication. All de-identified data resulting from this NIH-funded award will be submitted to the NIMH Data Archive (NDA) according to this timeline, along with appropriate supporting documentation to enable efficient use of the data by other researchers not involved in the study. Data derived from the proposed study will also be shared through presentation at research conferences and through publication in peer-reviewed journals.
- Access Criteria
- Data will be shared with researchers upon request. Other researchers across the world can then request the pseudo-anonymized study data for other research from the NDA. Every researcher (and institutions to which they belong) who requests the pseudo-anonymized study data must promise to keep the data safe. Experts at the NIH will review each request carefully to reduce risks to participant privacy.
Data will be uploaded to the NIH Data Archive (NDA).